On December 1, 2020 Immunomic Therapeutics, Inc. (ITI) reported that it will be presenting at the 2nd Annual Glioblastoma Drug Development Virtual Summit (Press release, Immunomic Therapeutics, DEC 1, 2020, View Source [SID1234572023]). On Wednesday, December 9th, Chief Executive Officer at ITI, Dr. Bill Hearl, will be presenting a talk titled, "Adaptive T-cell Immunotherapy for Newly Diagnosed Glioblastoma: Using Targeted Antigen Presentation to Enhance Immune Responses." Dr. Hearl will discuss ITI’s investigational platform technology, the company’s lead program and its preliminary data in GBM, as well as the company’s future focus.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follows:
Title: Adaptive T-cell Immunotherapy for Newly Diagnosed Glioblastoma: Using Targeted Antigen Presentation to Enhance Immune Responses
Presentation Category: Vaccines
Date and Time: Wednesday, December 9, 2020 12:40 PM EST / 9:40 AM PDT
Location: Virtual Summit
About UNITE
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein 1, an endogenous protein in humans, for immune processing. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach puts UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.